Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PREDICT inspection system in place by spring

This article was originally published in The Tan Sheet

Executive Summary

FDA will roll out the Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting risk assessment system nationwide this spring to better identify high-risk shipments at U.S. ports for inspection, Commissioner Margaret Hamburg says. PREDICT ranks import shipments' risk based on a variety of assessments, including whether a product is intrinsically risky, results from previous inspections of shippers and producers, market conditions and weather - such as floods or extreme heat - that could spoil a shipment, Hamburg explained Feb. 4 at the Center for Strategic and International Studies in Washington. FDA's first step is expanding its pilot program, begun in Los Angeles, to New York (1"The Tan Sheet" Dec. 21, 2009). Hamburg noted PREDICT is necessary because "it is simply not possible for FDA to inspect our way to safety.

You may also be interested in...



FDA Could Beef Up Food Safety Enforcement Through Inter-Agency Center

FDA expects its work in the Customs and Border Protection's new import tracing analysis center to generate information the agency can assimilate into its own supply-chain tracing capabilities

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel